Individual InvestorsEmployee ShareholdersInstitutional InvestorsPrivate Companies Accredited Investors Seed & Angel InvestorsAsset Managers & Hedge Funds Family Offices Venture Capital Firms Wealth Managers & RIAsWho We Serve TradingDataLiquidity ProgramsRetirement Individual InvestingForge MarketplaceFind new private company investment opportunitiesBrowse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolForge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companies Forge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All InsightsReports and highlightsNews and trendsPrivate market educationTips and tutorials Forge Investment Outlook Private Market Updates IPO calendar Private Magnificent 7Emerging trends Private company news Upcoming IPOsPrivate market basics Private shares transactions Valuations, pricing and market trends Selling in the private market FAQs GlossaryCompany page and trades Proof of ownership Bid and ask submissions Forge fund offeringsInsights About Us Leadership Investor Relations People & Culture Careers About

Parabilis Medicines stock

Highest bid

$XXXX

x/xx/xx

Lowest ask

$XXXX

x/xx/xx

Last matched price

$XXXX

x/xx/xx

Forge Price ¹

$--

Buy And Sell Parabilis Medicines StockLearn More About Parabilis Medicines IPOAdd To Watchlist

Parabilis Medicines stock price

Trade metrics

Market activity ²

Limited

Active bids

Active asks

Highest bid price

$ XXX.XX

Lowest ask price

$ XXX.XX

Total bids

$XXX

Total asks

$XXX

Last matched price

$ XXX.XX

xx/xx/xxxx

Last matched valuation

$ XXX.XX

xx/xx/xxxx

Access Stock Price

Price history chart

All

Forge Price

$--

Not yet available

Forge Price valuation

$--

Unlock Trading Activity

Most active Healthcare companies

Neuralink

See All Active Companies

Active market

Explore Market Activity

The image displayed is not current and any securities shown are for illustrative purposes only.

Forge exclusive fund offerings

The image displayed is not current and any securities shown are for illustrative purposes only.

Forge exclusive fund offerings

Access high-growth companies at a fixed price—for a limited time

Invest in trending companies with lower minimums

Simplify private investing through a Forge-managed single company fund

See Available Offerings

Parabilis Medicines stock FAQs

To buy and sell Parabilis Medicines stock

Can you buy Parabilis Medicines stock?

As Parabilis Medicines is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Parabilis Medicines, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

How to buy Parabilis Medicines stock?

To invest in a private company like Parabilis Medicines through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Parabilis Medicines stock?

Yes, you may sell the Parabilis Medicines stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Parabilis Medicines stock?

If you hold private company shares of Parabilis Medicines – whether as an employee or an early investor – Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Parabilis Medicines on our platform.
Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

To learn more about Parabilis Medicines stock

Is Parabilis Medicines a public company?

No, Parabilis Medicines is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Parabilis Medicines’ stock price?

Parabilis Medicines is a privately held company and therefore does not have a public stock price. However, you may access Parabilis Medicines private market stock price with Forge Data.

What is Parabilis Medicines’ stock ticker symbol?

Parabilis Medicines does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Parabilis Medicines funding rounds and valuation

Total funding $506.63MM

Funding history chart

Funding round details

	Funding Date	Share Class	Amount Raised	Price Per Share	Post-Money Valuation ³	Key Investors
	03/01/2024	Series E	$145MM	$6.23	$491.8MM	Alex Gorsky, Catalio Capital Management, Foresite Capital, General Catalyst, Marshall Wace, Nextech Invest, Ra Capital Management, Rock Springs Capital, Samsara Biocapital, Sixty Degree Capital, Symbiosis
Price Per Share $6.23 Shares Outstanding 23,281,563 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 8.0% Cumulative Cumulative Participating Participating Participation Cap 1000 Key Investors Alex Gorsky, Catalio Capital Management, Foresite Capital, General Catalyst, Marshall Wace, Nextech Invest, Ra Capital Management, Rock Springs Capital, Samsara Biocapital, Sixty Degree Capital, Symbiosis
	11/21/2022	Series D	$178MM	$10.76	$406.53MM	Arch Venture Partners, Casdin Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Fidelity, Gv, Hbm Healthcare Investments, Invus, Milky Way Investments, Pagsgroup, T. Rowe Price, Venbio Partners
Price Per Share $10.76 Shares Outstanding 16,537,979 Liquidation Pref Order 2 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.2x Dividend Rate 8.0% Cumulative Cumulative Participating Participating Participation Cap 1000 Key Investors Arch Venture Partners, Casdin Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Fidelity, Gv, Hbm Healthcare Investments, Invus, Milky Way Investments, Pagsgroup, T. Rowe Price, Venbio Partners
	03/01/2021	Series C	$107MM	$14.49	$262.08MM	6 Dimensions Capital, Blue Pool Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Gv, Invus, Venbio Partners
Price Per Share $14.49 Shares Outstanding 7,384,710 Liquidation Pref Order 3 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.4x Dividend Rate 8.0% Cumulative Cumulative Participating Participating Participation Cap 1000 Key Investors 6 Dimensions Capital, Blue Pool Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Gv, Invus, Venbio Partners
	05/16/2018	Series B	$65.51MM	$14.06	$131.82MM	6 Dimensions Capital, Blue Pool Capital, Boyu Capital, Deerfield Management, Gv, Horizons Ventures, Lerrink Partners, Nan Fung Group, Wuxi Apptec Corporate Ventures
Price Per Share $14.06 Shares Outstanding 4,658,112 Liquidation Pref Order 4 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.3x Dividend Rate 8.0% Cumulative Cumulative Participating Participating Participation Cap 1000 Key Investors 6 Dimensions Capital, Blue Pool Capital, Boyu Capital, Deerfield Management, Gv, Horizons Ventures, Lerrink Partners, Nan Fung Group, Wuxi Apptec Corporate Ventures
	05/25/2016	Series A	$11.11MM	$7.75	$37.05MM	Deerfield Management
Price Per Share $7.75 Shares Outstanding 1,434,062 Liquidation Pref Order 5 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.1x Dividend Rate 8.0% Cumulative Cumulative Participating Participating Participation Cap 1000 Key Investors Deerfield Management

Company details

Parabilis Medicines is a clinical-stage biotechnology research company striving to develop HeliconTM peptides, an innovative approach aimed at overcoming current medication limitations and creating drug solutions for all human disease drivers. The Helicons are intended to act similarly to antibodies and be allocated across tissue as they interact with small molecules within the cells, whereas most modern tailored medications have difficulty reaching these target areas. Parabilis Medicines was founded in 2016 and is headquartered in Cambridge, Massachusetts.

parabilismed.com

Sector

Healthcare

Subsector

Biotech & Pharma

Founded

2016

Headquarters

Cambridge, MA, United States

Leadership

Mathai Mammen MD, Ph.D.

Chief Executive Officer & President

Rohin Mhatre Ph.D

Chief Technical Operations Officer

Gregory Miller MPH, MBA

Chief Business Officer

Keith Orford MD

Chief Medical Officer & Executive Vice President of Clinical and Translational Science

Kristen Stants MILR

Chief People Officer

Board

Jeffrey Leerink

Leerink Partners

Krishna Yeshwant MD

Alexis Borisy

Nextech Invest

Parabilis Medicines investors also invested in these private compaies

6 Dimensions Capital

AnchorDx

Arch Venture Partners

Altos Labs, Xaira Therapeutics, Insitro, Resilience, Generate:Biomedicines, Chroma Medicine, Boundless Bio, Arbor Biotechnologies, Seaport Therapeutics, Moonwalk Biosciences

Blue Pool Capital

Boyu Capital

Timberlyne Therapeutics

Casdin Capital

Paige, Scorpion Therapeutics, Formation Bio, Aledade, 23andMe, Nusano, Asimov, LetsGetChecked, Vineti, Flare Therapeutics

Catalio Capital Management

Freenome, Imperative Care, Resilience, Iambic Therapeutics, NextPoint Therapeutics, Odyssey Therapeutics, Ensoma, Star Therapeutics, OnCusp Therapeutics, RefleXion Medical

Cormorant Asset Management

BioAge, Neurona Therapeutics, BlossomHill Therapeutics, Aardvark Therapeutics, Triveni Bio, Ensoma, Star Therapeutics, Myra Vision, Supira Medical, Alumis

Deerfield Management

Insilico Medicine, Cohere Health, Bicara Therapeutics, Frontier Medicines, Epic Sciences, Lark, Petfolk, LetsGetChecked, Crossover Health, Intus Care

Farallon Capital Management

HiBob, Freenome, Beta Bionics, Cardurion Pharma, Intarcia Therapeutics, Frete

Fidelity Management & Research

Epic Games, Tenstorrent, Waymo, Nuro, Astera Labs, Relativity Space, Ro, Checkr, Algolia, Kavak

Foresite Capital

Altos Labs, Mammoth Biosciences, Galileo Health, Kriya Therapeutics, Odyssey Therapeutics, Inscripta, Juvenescence, Obsidian Therapeutics, Element Biosciences, Delfi Diagnostics

General Catalyst

Anduril, Stripe, Nord Security, Canva, Helsing, Mistral AI, Ramp, Circle, Gusto, Anaconda

Ripple, Neuralink, Zipline, Cohesity, Vercel, SambaNova Systems, Nuro, ByteDance, dbt Labs, Neo4j

Hbm Healthcare Investments

Odyssey Therapeutics, Bluejay Therapeutics, Alumis

Horizons Ventures

Meesho, Inflection AI, Otter.ai, Divergent, BitPay, Wefox, Modern Meadow, Asimov, Perfect Day, Eikon Therapeutics

Leerink Partners

Milky Way Investments Group

Pagsgroup

Pivotal Life Sciences

Zenas BioPharma, Engrail Therapeutics, Obsidian Therapeutics

Ra Capital Management

X-energy, Bicara Therapeutics, Freenome, Synthego, Capstan Therapeutics, BioAge, Frontier Medicines, Boundless Bio, Sionna Therapeutics, Asher Biotherapeutics

Rock Springs Capital

Caris Life Sciences, Zenas BioPharma, Freenome, Imperative Care, Hemab Therapeutics, Vedanta Biosciences, Delfi Diagnostics, Mineralys, Kindbody

Samsara Biocapital

Alamar Biosciences, Obsidian Therapeutics, Delfi Diagnostics, Mineralys, Attralus, Alumis, Septerna, Spyglass Pharma, Acelyrin, RayzeBio

Sixty Degree Capital

Navan, NextPoint Therapeutics, Aqua Security, RefleXion Medical

Symbiosis Capital Management

Neurona Therapeutics, Aardvark Therapeutics, Biosplice Therapeutics, Endeavor BioMedicines, Ensoma, Saliogen Therapeutics

T. Rowe Price

Redwood Materials, Waymo, KoBold Metals, SandboxAQ, Tanium, Nuro, Rappi, Sila Nanotechnologies, Ro, Stash

The Invus Group

Scorpion Therapeutics, Bicara Therapeutics, Meow Wolf, Triveni Bio, Asher Biotherapeutics, PayJoy, Endeavor BioMedicines, Hemab Therapeutics, Lycia Therapeutics, Cardurion Pharma

Venbio

Intercom, Attralus, Alumis, Acelyrin, RayzeBio

Wuxi Apptec

Insilico Medicine, AnchorDx

Show More InvestorsShow Fewer Investors

Parabilis Medicines news and media highlights

Yahoo Finance 03/01/2024

FogPharma pulls in $145M to support cancer drug research

FogPharma elevated its financing with a series E funding round to continue its cancer pharmaceutical research expansion.

MedCity News 12/05/2022

FogPharma’s $178M Funding Leads Way as 7 Biotechs Raise Cash for Cancer Drugs.

FogPharma is preclinical, but not for long. The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs.

Inside Precision Medicine 11/29/2022

FogPharma Nets $178M Series D to Tackle Tough Targets

FogPharma has netted a $178 Million Series D financing to develop Helicon polypeptide therapeutics against hard targets.

PR Newswire 09/23/2019

FogPharma Expands Leadership Team with Key Appointments

/PRNewswire/ -- FogPharma today announced the appointment of Fang Wang, Ph.D., as Vice President of Biology and Nancy Wilker, Ph.D., J.D., as Vice President...

Browse More Insights

Other companies like Parabilis Medicines in the Biotech & Pharma sector

Sector: Healthcare

Subsector: Biotech & Pharma

Trade Metrics				Last Funding Round
Company		Forge Price	Last Matched Price	Share Class	Post-Money Valuation ³	Price Per Share	Amount Raised
	Altos Labs	--	$xx.xx	Series C	$6.33B	$25.02	$1.5B
	Apnimed	--	$xx.xx	Series D	$394.07MM	$9.65	$16.5MM
	Colossal Biosciences	--	$xx.xx	Series C	$10.2B	$24.89	$200MM
	Human Longevity	--	$xx.xx	Series B-1	$185.79MM	$0.31	$32MM
	Isomorphic Labs	--	$xx.xx	--	--	--	--
	Life Biosciences	--	$xx.xx	--	--	--	--
	Loyal	--	$xx.xx	Series B-5	$428.44MM	$10.64	$17.49MM
	Precision Neuroscience	--	$xx.xx	Series C	$542.69MM	$5.70	$102MM
	SetPoint Medical	--	$xx.xx	Series D	$471.62MM	$1.51	$115MM
	Shoulder Innovations	--	$xx.xx	--	--	--	--

See All Companies

Forge is your trusted partner to buy and sell Parabilis Medicines stock

Forge is the trusted platform for buying and selling private company stock. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

First time buying private market stock?

New to selling your private company stock?

Updated on: Jul 15, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
Most active companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.